BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, Maes T, Shi W, Stampfli M, Uhlig S, White E, Witzenrath M, Bellaye PS, Crestani B, Eickelberg O, Fehrenbach H, Guenther A, Jenkins G, Joos G, Magnan A, Maitre B, Maus UA, Reinhold P, Vernooy JHJ, Richeldi L, Kolb M. Optimising experimental research in respiratory diseases: an ERS statement. Eur Respir J 2018;51:1702133. [PMID: 29773606 DOI: 10.1183/13993003.02133-2017] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Artzy-schnirman A, Lehr C, Sznitman J. Advancing human in vitro pulmonary disease models in preclinical research: opportunities for lung-on-chips. Expert Opinion on Drug Delivery 2020;17:621-5. [DOI: 10.1080/17425247.2020.1738380] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Noe N, Shim A, Millette K, Luo Y, Azhar M, Shi W, Warburton D, Turcatel G. Mesenchyme-specific deletion of Tgf-β1 in the embryonic lung disrupts branching morphogenesis and induces lung hypoplasia. Lab Invest 2019;99:1363-75. [PMID: 31028279 DOI: 10.1038/s41374-019-0256-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Yanagihara T, Chong SG, Vierhout M, Hirota JA, Ask K, Kolb M. Current models of pulmonary fibrosis for future drug discovery efforts. Expert Opin Drug Discov 2020;15:931-41. [PMID: 32396021 DOI: 10.1080/17460441.2020.1755252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gribaldo L, Hurley K, Hiemstra P, Greene C. Increased focus on non-animal models for COVID-19 and non-COVID lung research. Eur Respir J 2021;57:2004267. [PMID: 33446578 DOI: 10.1183/13993003.04267-2020] [Reference Citation Analysis]
5 Bordenave J, Thuillet R, Tu L, Phan C, Cumont A, Marsol C, Huertas A, Savale L, Hibert M, Galzi JL, Bonnet D, Humbert M, Frossard N, Guignabert C. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovasc Res 2020;116:686-97. [PMID: 31173066 DOI: 10.1093/cvr/cvz153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
6 Feary JR, Schofield SJ, Canizales J, Fitzgerald B, Potts J, Jones M, Cullinan P. Laboratory animal allergy is preventable in modern research facilities. Eur Respir J 2019;53:1900171. [PMID: 30956209 DOI: 10.1183/13993003.00171-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Mekhael O, Naiel S, Vierhout M, Hayat AI, Revill SD, Abed S, Inman MD, Kolb MRJ, Ask K. Mouse Models of Lung Fibrosis. Methods Mol Biol 2021;2299:291-321. [PMID: 34028751 DOI: 10.1007/978-1-0716-1382-5_21] [Reference Citation Analysis]
8 Shimbori C, Upagupta C, Bellaye PS, Ayaub EA, Sato S, Yanagihara T, Zhou Q, Ognjanovic A, Ask K, Gauldie J, Forsythe P, Kolb MRJ. Mechanical stress-induced mast cell degranulation activates TGF-β1 signalling pathway in pulmonary fibrosis. Thorax 2019;74:455-65. [PMID: 30808717 DOI: 10.1136/thoraxjnl-2018-211516] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
9 Huertas A, Tu L, Humbert M, Guignabert C. Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovasc Res. 2020;116:885-893. [PMID: 31813986 DOI: 10.1093/cvr/cvz308] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
10 Viana F, O'Kane CM, Schroeder GN. Precision-cut lung slices: A powerful ex vivo model to investigate respiratory infectious diseases. Mol Microbiol 2021. [PMID: 34570407 DOI: 10.1111/mmi.14817] [Reference Citation Analysis]
11 Günther S, Bordenave J, Hua-Huy T, Nicco C, Cumont A, Thuillet R, Tu L, Quatremarre T, Guilbert T, Jalce G, Batteux F, Humbert M, Savale L, Guignabert C, Dinh-Xuan AT. Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. Int J Mol Sci 2018;19:E4105. [PMID: 30567353 DOI: 10.3390/ijms19124105] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
12 Hiemstra PS, Sterk PJ. Translation of in vitro findings to patients with asthma: a timely and compelling challenge. Eur Respir J 2019;54:1901759. [PMID: 31601723 DOI: 10.1183/13993003.01759-2019] [Reference Citation Analysis]
13 Witzenrath M, Kuebler WM. Pneumonia in the face of COVID-19. Am J Physiol Lung Cell Mol Physiol 2020;319:L863-6. [PMID: 32996786 DOI: 10.1152/ajplung.00447.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Beike L, Wrede C, Hegermann J, Lopez-Rodriguez E, Kloth C, Gauldie J, Kolb M, Maus UA, Ochs M, Knudsen L. Surfactant dysfunction and alveolar collapse are linked with fibrotic septal wall remodeling in the TGF-β1-induced mouse model of pulmonary fibrosis. Lab Invest 2019;99:830-52. [PMID: 30700849 DOI: 10.1038/s41374-019-0189-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
15 Bain W, Matute-Bello G. Should we shift the paradigm of preclinical models for ARDS therapies? Thorax 2019;74:1109-10. [PMID: 31624219 DOI: 10.1136/thoraxjnl-2019-213729] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Oakley C, Koh M, Baldi R, Soni S, O'Dea K, Takata M, Wilson M. Ventilation following established ARDS: a preclinical model framework to improve predictive power. Thorax 2019;74:1120-9. [PMID: 31278170 DOI: 10.1136/thoraxjnl-2019-213460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 He G, Chen K, Wang H, Li X, Li W, liu L, Chen J, Yang D, Hu J, Xu D, Wen F, Wang T. Fudosteine attenuates acute lung injury in septic mice by inhibiting pyroptosis via the TXNIP/NLRP3/GSDMD pathway. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175047] [Reference Citation Analysis]
18 Farré R, Hiemstra PS, Dinh-Xuan AT. Basic and translational research in the European Respiratory Journal. Eur Respir J 2018;51:1800377. [PMID: 29724787 DOI: 10.1183/13993003.00377-2018] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Khouri C, Mahé J, Caquelin L, Locher C, Despas F. Pharmacology and pharmacovigilance of protein kinase inhibitors. Therapie 2021:S0040-5957(21)00242-0. [PMID: 34895753 DOI: 10.1016/j.therap.2021.11.004] [Reference Citation Analysis]
20 Hewitt RJ, Maher TM. Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options. Drugs Aging 2019;36:485-92. [DOI: 10.1007/s40266-019-00647-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
21 Farré R, Martínez-García MA, Gozal D. Systematic reviews and meta-analyses in animal model research: as necessary, and with similar pros and cons, as in patient research. Eur Respir J 2022;59:2102438. [PMID: 35301241 DOI: 10.1183/13993003.02438-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Burgy O, Bellaye PS, Beltramo G, Goirand F, Bonniaud P. Pathogenesis of fibrosis in interstitial lung disease. Curr Opin Pulm Med 2020;26:429-35. [PMID: 32769673 DOI: 10.1097/MCP.0000000000000706] [Reference Citation Analysis]
23 Dudal S, Bissantz C, Caruso A, David-Pierson P, Driessen W, Koller E, Krippendorff BF, Lechmann M, Olivares-Morales A, Paehler A, Rynn C, Türck D, Van De Vyver A, Wang K, Winther L. Translating pharmacology models effectively to predict therapeutic benefit. Drug Discov Today 2022:S1359-6446(22)00117-9. [PMID: 35304340 DOI: 10.1016/j.drudis.2022.03.009] [Reference Citation Analysis]
24 Kolb P, Upagupta C, Vierhout M, Ayaub E, Bellaye PS, Gauldie J, Shimbori C, Inman M, Ask K, Kolb MRJ. The importance of interventional timing in the bleomycin model of pulmonary fibrosis. Eur Respir J 2020;55:1901105. [PMID: 32165401 DOI: 10.1183/13993003.01105-2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
25 Hiemstra PS, Tetley TD, Janes SM. Airway and alveolar epithelial cells in culture. Eur Respir J 2019;54:1900742. [DOI: 10.1183/13993003.00742-2019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
26 Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, Rounseville SP, Krafty RT, Wollin L, Sauler M, Hecker L. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. Eur Respir J 2021;58:2100759. [PMID: 34531276 DOI: 10.1183/13993003.00759-2021] [Reference Citation Analysis]
27 Pu X, Du L, Hu Y, Fan Y, Xu Q. Stem/Progenitor Cells and Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol 2021;41:167-78. [PMID: 33028095 DOI: 10.1161/ATVBAHA.120.315052] [Reference Citation Analysis]
28 Roche N, Tonia T, Miravitlles M, Vaccaro V, Genton C, Welte T, Troosters T, Brusselle G, Brightling C. Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards. Eur Respir J 2020;55:2001030. [PMID: 32499310 DOI: 10.1183/13993003.01030-2020] [Reference Citation Analysis]
29 Liebler-Tenorio EM, Lambertz J, Ostermann C, Sachse K, Reinhold P. Regeneration of Pulmonary Tissue in a Calf Model of Fibrinonecrotic Bronchopneumonia Induced by Experimental Infection with Chlamydia Psittaci. Int J Mol Sci 2020;21:E2817. [PMID: 32316620 DOI: 10.3390/ijms21082817] [Reference Citation Analysis]
30 Albert K, Krischer JM, Pfaffenroth A, Wilde S, Lopez-Rodriguez E, Braun A, Smith BJ, Knudsen L. Hidden Microatelectases Increase Vulnerability to Ventilation-Induced Lung Injury. Front Physiol 2020;11:530485. [PMID: 33071807 DOI: 10.3389/fphys.2020.530485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Mahmutovic Persson I, von Wachenfeldt K, Waterton JC, Olsson LE, On Behalf Of The Tristan Consortium. Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review. J Clin Med 2020;10:E107. [PMID: 33396865 DOI: 10.3390/jcm10010107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Artzy-Schnirman A, Arber Raviv S, Doppelt Flikshtain O, Shklover J, Korin N, Gross A, Mizrahi B, Schroeder A, Sznitman J. Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics. Adv Drug Deliv Rev 2021;176:113901. [PMID: 34331989 DOI: 10.1016/j.addr.2021.113901] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
33 Maes T, Brusselle GG. Simultaneous inhibition of thymic stromal lymphopoietin, IL-33 and IL-25: A therapeutic option in asthma? Respirology 2020;25:566-7. [PMID: 31769190 DOI: 10.1111/resp.13748] [Reference Citation Analysis]
34 Luo Y, Yi H, Huang X, Lin G, Kuang Y, Guo Y, Xie C. Inhibition of macrophage migration inhibitory factor (MIF) as a therapeutic target in bleomycin-induced pulmonary fibrosis rats. Am J Physiol Lung Cell Mol Physiol 2021;321:L6-L16. [PMID: 33881353 DOI: 10.1152/ajplung.00288.2020] [Reference Citation Analysis]
35 Jalce G, Guignabert C. Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology 2020;318:L1-9. [DOI: 10.1152/ajplung.00234.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Sinha P, Bos LD. Pathophysiology of the Acute Respiratory Distress Syndrome: Insights from Clinical Studies. Crit Care Clin 2021;37:795-815. [PMID: 34548134 DOI: 10.1016/j.ccc.2021.05.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Fröhlich E. Replacement Strategies for Animal Studies in Inhalation Testing. Sci 2021;3:45. [DOI: 10.3390/sci3040045] [Reference Citation Analysis]
38 Yaqub N, Wayne G, Birchall M, Song W. Recent advances in human respiratory epithelium models for drug discovery. Biotechnol Adv 2021;:107832. [PMID: 34481894 DOI: 10.1016/j.biotechadv.2021.107832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Cloer C, Roudsari L, Rochelle L, Petrie T, Welch M, Charest J, Tan K, Fugang L, Petersen T, Ilagan R, Hogan S. Mesenchymal stromal cell-derived extracellular vesicles reduce lung inflammation and damage in nonclinical acute lung injury: Implications for COVID-19. PLoS One 2021;16:e0259732. [PMID: 34780505 DOI: 10.1371/journal.pone.0259732] [Reference Citation Analysis]
40 Orihuela CJ, Maus UA, Brown JS. Can animal models really teach us anything about pneumonia? Pro. Eur Respir J 2020;55:1901539. [DOI: 10.1183/13993003.01539-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Persson C. In vivo observations provide insight into roles of eosinophils and epithelial cells in asthma. Eur Respir J 2019;54:1900470. [PMID: 31248957 DOI: 10.1183/13993003.00470-2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Burgy O, Armitage J, Wain L, Casas M, Mantoani LC, Bodier-Montagutelli E, Boccabella C, De Brandt J. ERS International Congress 2018: highlights from best-abstract awardees. Breathe (Sheff) 2018;14:e137-42. [PMID: 30820255 DOI: 10.1183/20734735.0337-2018] [Reference Citation Analysis]
43 Lehr CM, Yeo L, Sznitman J. Editorial: Innovative In Vitro Models for Pulmonary Physiology and Drug Delivery in Health and Disease. Front Bioeng Biotechnol 2021;9:788682. [PMID: 34746115 DOI: 10.3389/fbioe.2021.788682] [Reference Citation Analysis]
44 Ladjemi MZ, Burgel PR, Pilette C. Reply to Polverino: Deconvoluting Chronic Obstructive Pulmonary Disease: Are B Cells the Frontrunners? Am J Respir Crit Care Med 2019;199:1171-2. [PMID: 30633554 DOI: 10.1164/rccm.201812-2249LE] [Reference Citation Analysis]
45 Vanderstocken G, Marrow JP, Allwood MA, Stampfli MR, Simpson JA. Disruption of Physiological Rhythms Persist Following Cessation of Cigarette Smoke Exposure in Mice. Front Physiol 2020;11:501383. [PMID: 33192539 DOI: 10.3389/fphys.2020.501383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Chaumais MC, Djessas MRA, Thuillet R, Cumont A, Tu L, Hebert G, Gaignard P, Huertas A, Savale L, Humbert M, Guignabert C. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovasc Res 2021;117:1391-401. [PMID: 32653925 DOI: 10.1093/cvr/cvaa200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Krauss E, Haberer J, Maurer O, Barreto G, Drakopanagiotakis F, Degen M, Seeger W, Guenther A. Exploring the Ability of Electronic Nose Technology to Recognize Interstitial Lung Diseases (ILD) by Non-Invasive Breath Screening of Exhaled Volatile Compounds (VOC): A Pilot Study from the European IPF Registry (eurIPFreg) and Biobank. J Clin Med 2019;8:E1698. [PMID: 31623141 DOI: 10.3390/jcm8101698] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
48 Mahmutovic Persson I, Falk Håkansson H, Örbom A, Liu J, von Wachenfeldt K, Olsson LE. Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease Induced by Bleomycin. Front Physiol 2020;11:584. [PMID: 32636756 DOI: 10.3389/fphys.2020.00584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Khedoe PPPSJ, Wu X, Gosens R, Hiemstra PS. Repairing damaged lungs using regenerative therapy. Curr Opin Pharmacol 2021;59:85-94. [PMID: 34161852 DOI: 10.1016/j.coph.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Poble P, Phan C, Quatremare T, Bordenave J, Thuillet R, Cumont A, Huertas A, Tu L, Dorfmüller P, Humbert M, Ghigna M, Savale L, Guignabert C. Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB j 2018;33:3670-9. [DOI: 10.1096/fj.201801659r] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, Revol B, Despas F, Montani D, Cracowski JL. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. Eur Respir J 2019;53:1802472. [PMID: 30846469 DOI: 10.1183/13993003.02472-2018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
52 Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019;53:1801887. [PMID: 30545970 DOI: 10.1183/13993003.01887-2018] [Cited by in Crossref: 305] [Cited by in F6Publishing: 264] [Article Influence: 101.7] [Reference Citation Analysis]
53 Patete CL, Toonkel RL, Glassberg M. Stem Cell Based Therapy for Lung Disease Preclinical evidence for the role of stem/stromal cells Clinical application of stem/stromal cells in lung fibrosis. In: Burgess JK, Heijink IH, editors. Stem Cell-Based Therapy for Lung Disease. Cham: Springer International Publishing; 2019. pp. 119-30. [DOI: 10.1007/978-3-030-29403-8_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Cigana C, Ranucci S, Rossi A, De Fino I, Melessike M, Bragonzi A. Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa. Eur Respir J 2020;55:1802456. [PMID: 31624114 DOI: 10.1183/13993003.02456-2018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
55 Engelmann TA, Knudsen L, Leitz DHW, Duerr J, Beers MF, Mall MA, Ochs M. Linking Fibrotic Remodeling and Ultrastructural Alterations of Alveolar Epithelial Cells after Deletion of Nedd4-2. Int J Mol Sci 2021;22:7607. [PMID: 34299227 DOI: 10.3390/ijms22147607] [Reference Citation Analysis]
56 Ruscitti F, Ravanetti F, Bertani V, Ragionieri L, Mecozzi L, Sverzellati N, Silva M, Ruffini L, Menozzi V, Civelli M, Villetti G, Stellari FF. Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography. Front Pharmacol 2020;11:1117. [PMID: 32792953 DOI: 10.3389/fphar.2020.01117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
57 Nikolić MZ, Garrido-Martin EM, Greiffo FR, Fabre A, Heijink IH, Boots A, Greene CM, Hiemstra PS, Bartel S. From the pathophysiology of the human lung alveolus to epigenetic editing: Congress 2018 highlights from ERS Assembly 3 "Basic and Translational Science.". ERJ Open Res 2019;5:00194-2018. [PMID: 31111040 DOI: 10.1183/23120541.00194-2018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Fieldès M, Ahmed E, Bourguignon C, Mianné J, Vernisse C, Fort A, Vachier I, Bourdin A, Assou S, De Vos J. [Modelling the bronchial epithelium in chronic obstructive pulmonary disease using human induced pluripotential stem cells]. Rev Mal Respir 2020;37:197-200. [PMID: 32146059 DOI: 10.1016/j.rmr.2020.02.003] [Reference Citation Analysis]